Magenta Therapeutics Announces Update on US FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Magenta Therapeutics, Inc. announced that it has received a clinical hold letter from the US FDA related to its Investigational New Drug Application filed in June 2021 to initiate a Phase I/II clinical trial of MGTA-117 in patients with acute myeloid leukemia and myelodysplastic syndrome.